Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
Hiro

35 results about "Dysthymia disorder" patented technology

Dysthymia, now known as persistent depressive disorder (PDD), is a mood disorder consisting of the same cognitive and physical problems as depression, with less severe but longer-lasting symptoms.

Extended Release Pharmaceutical Formulations of S-Adenosylmethionine

Extended release formulations of S-methyladenosylmethionine (SAMe) are provided, as are methods of treating various disorders using extended release SAMe formulations. The extended release formulations may be used to treat a variety of disorders, including liver disorders, psychiatric disorders and joint disorders. Thus, extended release SAMe formulations may be used to treat alcoholic liver disease, fatty liver disease, hepatitis, generalized anxiety disorder, obsessive compulsive disorder, post traumatic stress disorder, panic disorder, and depressive disorders such as depression (e.g. major clinical depression) and dysthymia.
Owner:METILEJSHN SAJENSIS INT SRL

Extended Release Pharmaceutical Formulations of S-Adenosylmethionine

Extended release formulations of S-methyladenosylmethionine (SAMe) are provided, as are methods of treating various disorders using extended release SAMe formulations. The extended release formulations may be used to treat a variety of disorders, including liver disorders, psychiatric disorders and joint disorders. Thus, extended release SAMe formulations may be used to treat alcoholic liver disease, fatty liver disease, hepatitis, generalized anxiety disorder, obsessive compulsive disorder, post traumatic stress disorder, panic disorder, and depressive disorders such as depression (e.g. major clinical depression) and dysthymia.
Owner:METILEJSHN SAJENSIS INT SRL

Use of enantiomeric pure escitalopram

InactiveUS20040192765A1BiocideNervous disorderAcute Stress DisorderEscitalopram
The present invention relates to the use of anatiomeric pure escitalopram and / or of low dose medicaments thereof for the improved treatment of depression, in particular major depression disorder, neurotic disorders, acute stress disorder, eating disorders such as bulimia, anorexia and obesity, phobias, dysthymia, pre-mentrual syndrome, cognitive disorders, impulse control disorders, attention deficit hyperactivity disorder or drug abuse. The medicaments may also be used in the treatment of major depression disorder in "treatment resistant" patients.
Owner:H LUNDBECK AS

Extended Release Pharmaceutical Formulations of S-Adenosylmethionine

Extended release formulations of S-methyladenosylmethionine (SAMe) are provided, as are methods of treating various disorders using extended release SAMe formulations. The extended release formulations may be used to treat a variety of disorders, including liver disorders, psychiatric disorders and joint disorders. Thus, extended release SAMe formulations may be used to treat alcoholic liver disease, fatty liver disease, hepatitis, generalized anxiety disorder, obsessive compulsive disorder, post traumatic stress disorder, panic disorder, and depressive disorders such as depression (e.g. major clinical depression) and dysthymia.
Owner:METILEJSHN SAJENSIS INT SRL

Methods for diagnosing mood disorders

The present invention relates to methods of diagnosing, prognosing or treating diseases or disorders in which elevated levels of Aβ protein, including Aβ1-42 are prevalent. In particular, the present invention relates to methods of diagnosing, prognosing or treating a mood disorder such as a major or minor depressive disorder or dysthymia attributed to reduced levels of Aβ protein, including Aβ1-42, found particularly in body fluids including whole blood, blood cells, serum, plasma, urine and CSF. The invention also relates to the treatment of these disorders and methods of identifying subjects who may respond positively to such treatment by administering an agent that either prevents production of Aβ, prevents aggregation of Aβ fibrils, that increases the degradation or clearance of Aβ or that prevents or interferes with Abeta-induced neurotoxicity.
Owner:NEW YORK UNIV

Traditional Chinese medicine composition for treating dysthymia

The invention relates to a traditional Chinese medicine composition for treating dysthymia, belonging to traditional Chinese medicines. The traditional Chinese medicine composition for treating dysthymia is prepared from the following active pharmaceutical ingredients in parts by weight: 27-33 parts of rhizoma cyperi, 8-12 parts of hemlock parsley, 8-12 parts of gardenia, 8-12 parts of rhizoma atractylodis, 27-33 parts of poria with hostwood, 12-18 parts of angelica and 8-12 parts of radix bupleuri. According to the traditional Chinese medicine theoretical formula, the modern pharmacological experimental method sufficiently proves that the traditional Chinese medicine composition for treating dysthymia has the functions of soothing the liver, regulating the flow of qi and relieving the depressed liver, is used for treating dysthymia, and is suitable for patients with depression and stagnation of the liver-qi in traditional Chinese medicine.
Owner:王剑

A robot for music-assisted physiotherapy for mental depression

A robot for music-assisted physiotherapy for mental depression, which is composed of a body and a power circuit, an inductive sensor, a transponder and a player. The upper part of the body is the robot head, and the lower part is the feet. Start switch and close switch, inductive sensor, system processor and pronunciation device are formed, and inductive sensor is arranged on the top of robot, and start and close switch and plug are arranged on body and biped. When the patient needs to relieve stress, turn on the power, turn on the switch, and play comforting sounds, soothing light music and happy songs through man-machine dialogue interaction induction to relieve the patient's mental stress.
Owner:龙梅

Antidepressant cycloalkylamine derivatives of heterocycle-fused benzodioxans

Compounds of the formula: are useful for the treatment of depression (including but not limited to major depressive disorder, childhood depression and dysthymia), anxiety, panic disorder, post-traumatic stress disorder, premenstrual dysphoric disorder (also known as pre-menstrual syndrome), attention deficit disorder (with and without hyperactivity), obsessive-compulsive disorder, social anxiety disorder, generalized anxiety disorder, obesity, eating disorders, vasomotor flushing, cocaine and alcohol addiction, sexual dysfunction and related illnesses.
Owner:WYETH LLC

4-[2,3-Difluoro-6-(2-fluoro-4-methyl-phenylsulfanyl)-phenyl]-piperidine

The compound 4-[2,3-Difluoro-6-(2-fluoro-4-methyl-phenylsulfanyl)-phenyl]-piperidine according to the structure (formula I), and pharmaceutically acceptable salts thereof are provided for the treatment of CNS related disorders, such as: depressive disorder, dysthymic disorder; mood disorder due to a general medical condition; atypical depression; seasonal affective disorder; melancholia; treatment resistant depression; partial responders; depression associated with bipolar disorder, pain, Alzheimer's disease, psychosis, Parkinson's disease, Lewy body disease, Huntington's disease, multiple sclerosis or anxiety; general anxiety disorder, social anxiety disorder, panic attacks; phobia; social phobia, obsessive compulsive disorder; post traumatic stress disorder, acute stress; ADHD; and pain.
Owner:H LUNDBECK AS

Medicament for treating dysthymia

The invention relates to a medicament for treating dysthymia. The medicament is prepared from the following substances in parts by weight: 5-10 parts of radix scrophulariae, 10-20 parts of rhizoma zingiberis, 20-30 parts of dogwood, 10-20 parts of platycodon grandiflorum, 15-25 parts of goldthread, 5-15 parts of chrysanthemum, 10-30 parts of golden-rod, 1-15 parts of henbane, 10-20 parts of ephedra, 15-30 parts of pyrrosia lingua, 20-30 parts of tabasheer, 1-20 parts of morinda officinalis, 1-20 parts of rhizoma dioscoreae, 10-25 parts of lalang grass rhizome, 10-30 parts of cocklebur fruit, 1-20 parts of emblic leafflower fruit, 15-20 parts of kamuning, 10-20 parts of kaladana, 15-20 parts of herba inulae, 15-30 parts of herb of glabrous sarcandra, 10-20 parts of fructus aristolochiae, 10-25 parts of folium sennae, 5-15 parts of aleppo avens, 1-20 parts of uniflower swisscentaury root, 15-25 parts of rhododendron dauricum, 15-25 parts of potentilla discolor, 10-20 parts of chinese lantern-plant, 15-25 parts of root bark of white mulberry, 20-30 parts of common vladimiria root, 1-20 parts of gorgon fruit and 10-25 parts of chinese azalea flower. All components of the medicament for treating dysthymia disclosed by the invention are natural materials; and the medicament is good in security, definite in curative effect, and suitable for large-scale clinical popularization.
Owner:高新华

Antidepressant azaheterocyclylmethyl derivatives of 7,8-dihydro-6H-5-oxa-1-aza-phenanthrene

Compounds of the formula useful for the treatment of such as depression (including but not limited to major depressive disorder, childhood depression and dysthymia), anxiety, panic disorder, post-traumatic stress disorder, premenstrual dysphoric disorder (also known as premenstrual syndrome), attention deficit disorder (with and without hyperactivity), obsessive compulsive disorder (including trichotillomania), social anxiety disorder, generalized anxiety disorder, obesity, eating disorders such as anorexia nervosa, bulimia nervosa, vasomotor flushing, cocaine and alcohol addition, sexual dysfunction (including premature ejaculation), and related illnesses.
Owner:WYETH LLC
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products